Anti-CD19 CAR T Infusion Combined With Allogeneic Stem Cell Transplantation for B-cell Leukemia/Lymphoma
Status:
Unknown status
Trial end date:
2021-09-01
Target enrollment:
Participant gender:
Summary
This is a single-arm open-label phase I study to determine the effect of CD19- CAR-T Cells
infusion followed by allogeneic stem cell transplantation in safety, efficacy and engraftment
potential in patients with CD19+ B-lineage leukemia and lymphoma.
Phase:
Phase 1
Details
Lead Sponsor:
First Affiliated Hospital of Wenzhou Medical University
Collaborators:
Hrain Biotechnology Co., Ltd. Second Affiliated Hospital of Nanchang University